N@N

VITA, STXS, LDL, AHD, OXGN, NTE Expected To Be Lower After Earnings Releases on Monday

^{Published on 2010-07-30 06:52:57, Last Modified on 2010-12-22 18:37:48 - WOPRAI}
 

July 30, 2010 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Monday, July 30th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and July earnings reports. Orthovita (NASDAQ: VITA), Stereotaxis (NASDAQ: STXS), Lydall (NYSE: LDL), Atlas Pipeline Holdings (NYSE: AHD), OXiGENE (NASDAQ: OXGN) and Nam Tai Electronics (NYSE: NTE) are all expected to be lower after their earnings are released Monday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go lower after earnings are released Monday:

Symbol Company # of Reports Quarter Release Time

VITA Orthovita, Inc. August earnings Q2 After

STXS Stereotaxis, Inc. 12 quarters Q2 After

LDL Lydall Inc 12 quarters Q2 Before

AHD Atlas Pipeline Holdings 12 quarters Q2 After

OXGN OXiGENE, Inc. 12 quarters Q2 Before

NTE Nam Tai Electronics 12 quarters Q2 Before

Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company.

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

Orthovita, Inc. (NASDAQ: VITA), a specialty spine and orthopedic company, develops and markets orthobiologic and biosurgery products. The companya�s orthobiologics platform offers products for the fusion, regeneration, and fixation of human bone; and the biosurgery platform provides products for controlling intra-operative bleeding/hemostasis. Its orthobiologic product portfolio comprises Vitoss bone graft substitute, a high-porous resorbable beta-tricalcium phosphate bone graft substitute used to help the body guide the three-dimensional regeneration of the patienta�s own bone; Bone Marrow Aspiration System with imbibe needles, syringes, and imbibe disposable delivery instrumentation, which provides spine and orthopedic surgeons with a method for harvesting a patienta�s own bone marrow; Cortoss Bone Augmentation Material, a polymer composite for use in various surgical procedures to provide structural stability and reinforcement of the bones after surgery; and Aliquot Delivery System that facilitates delivery of materials to bony sites, including delivery of Cortoss product directly to the surgical site. The companya�s biosugery products include Vitagel surgical hemostat, a composite liquid hemostat that combines the biomaterials bovine thrombin and bovine collagen with the patienta�s autologous plasma, and applied in the spine, hip, and knee replacement surgeries; and Vitasure Absorbable Hemostat, a plant-based hemostat product that can be deployed throughout surgery. It sells its products in the United States and internationally through a network of direct sales representatives and independent non-stocking distributors. The company has strategic partnerships with Kensey Nash Corporation; Angiotech Pharmaceuticals (U.S.), Inc.; and Medafor, Inc. Orthovita was founded in 1992 and is headquartered in Malvern, Pennsylvania.

Stereotaxis, Inc. (NASDAQ: STXS) designs, manufactures, and markets cardiology instrument control system for use in hospitala�s interventional surgical suite or interventional lab to treat arrhythmias and coronary artery disease in the United States and internationally. The company offers Niobe system, which comprises Niobe Magnetic Navigation System that navigates catheters, guidewires, and other delivery devices through the blood vessels and chambers of the heart to treatment sites; Navigant, an advanced user interface or physician control center, which helps physicians to visualize and track procedures and to provide instrument control commands that govern the motion of the working tip of the catheter, guidewire, or other interventional device; and Cardiodrive, an automated catheter advancement system to remotely advance and retract the catheter in the patienta�s heart. It also offers Odyssey Enterprise Solution, which provides information solution to manage, control, record, and share procedures across networks; acquire remote view of the lab capturing synchronized procedure data for review of important events during cases; and review recorded cases and create snapshots following procedures for clinical reporting, auditing, and presentation. In addition, the company markets and sells various disposable interventional devices, including catheters, guidewires, and other delivery devices. Stereotaxis markets its products through direct sales force, distributors, and sales agents. It has strategic partnerships with Siemens AG Medical Solutions, Philips Medical Systems, and Biosense Webster, Inc. The company was founded in 1990 and is based in St. Louis, Missouri.

Lydall, Inc. (NYSE: LDL) designs and manufactures specialty engineered products for the thermal/acoustical, filtration/separation, and bio/medical applications. It operates in two segments, Performance Materials and Thermal/Acoustical. The Thermal/Acoustical segment offers automotive thermal and acoustical barriers, including organic and inorganic fiber composites, metal combinations, and metal components that are used in cars, trucks, sport utility vehicles, heavy duty trucks, buses, and military and recreational vehicles. The Performance Materials segment provides filtration media solutions for air, fluid power, industrial, and life science applications; and industrial thermal insulation solutions for building products, appliances, energy, and industrial markets. Lydall, Inc. also develops non-woven veils, mats, and specialty composites for the building products, appliance, energy, and industrial markets. In addition, it offers specialty products for blood transfusion and cell therapy applications in the life science industry, as well as Bio-Pak single-use bioprocessing containers for the containment of media, buffers, and bulk intermediates used in biotech, pharmaceutical, and diagnostic reagent manufacturing processes. Further, it offers Cell-Freeze, medical device used for the cryogenic storage of peripheral blood stem cells; specialty blood transfusion products, and medical filtration components used for surgical procedures. Further, the company designs and manufactures high precision, specialty engineered temperature-control equipment for semiconductor, pharmaceutical, life sciences, and industrial applications. Lydall, Inc. sells its products to original equipment manufacturers and tier-one suppliers in the United States, Mexico, Canada, Europe, and Asia. The company was founded in 1913 and is based in Manchester, Connecticut.

Atlas Pipeline Holdings, L.P. (NYSE: AHD), a midstream energy service company, together with its subsidiaries, engages in the transmission, gathering, and processing of natural gas in the Mid-Continent and Appalachia regions. As of December 31, 2009, the company owned and operated 8 natural gas processing plants with aggregate capacity of approximately 900 million cubic feet per day (MMCFD); and 1 treating facility with a capacity of approximately 200 MMCFD. The company also operated 9,100 miles of active natural gas gathering systems located in Oklahoma, Kansas, and Texas, which gathers gas from wells and central delivery points to companya�s natural gas processing and treating plants, as well as third-party pipelines. In addition, it owned and operated approximately 1,800 miles of natural gas gathering systems in the Appalachian Basin; and approximately 80 miles of active natural gas gathering pipelines located in northeastern Tennessee. Atlas Pipeline Partners, L.P. operates as the general partner to Atlas Pipeline Holdings, L.P. The company is based in Moon Township, Pennsylvania.

OXiGENE, Inc. (NASDAQ: OXGN), a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat cancer and eye diseases in the United States. It primarily focuses on the development of product candidates that disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, as well as associate with visual impairment in various ophthalmological diseases and conditions. The companya�s products include ZYBRESTAT, which is in FALCON Trial - Phase II randomized controlled study for the treatment of 1st-line non-small cell lung cancer, as well as in Phase II Simon two-stage design study for the treatment of platinum-resistant ovarian cancer; and OXi4503 that is in Phase I dose-escalation study and Phase Ib dose-ranging study for the treatment of refractory solid tumors hepatic tumors. Its products also include ZYBRESTAT for ophthalmology, which is in phase II randomized, double-masked, placebo-controlled, and single-dose study for proof-of-mechanism study in polypoidal choroidal vasculopathy. OXiGENE has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology, and OXi4503. The company was founded in 1988 and is headquartered in South San Francisco, California.

Nam Tai Electronics, Inc. (NYSE: NTE) provides electronics manufacturing and design services to the original equipment manufacturers of telecommunication and consumer electronic products. The companya�s Consumer Electronic and Communication Products segment manufactures mobile phone accessories, such as headsets containing Bluetooth wireless technology, and phone cradles, as well as snap-on portable music speaker, FM radio adaptors, and GPS adaptors; entertainment devices, including USB Web cam for interactive games, USB microphone and converter box Karaoke, and buzzer devices for quiz games; educational products, such as digital pens, calculators, and electronic dictionaries; and optical devices comprising CMOS imaging sensor modules for notebook computers, portable media players, and recording cameras. Nam Taia�s Telecommunication Component Assembly segment provides subassemblies and components, such as color and monochrome LCD modules for PDA phones, smart phones, mobile phones, and telephone systems; RF modules for integration into mobile phones; DAB modules for digital radio products, such as home tuners, kitchen radios, in-car receivers, CD players, clock radios, boom boxes, midi-systems, and handheld portable devices; FPC subassemblies for LCD modules and electronic devices; FPC boards for mobile phones, PDAs, office automation, and laptop computers; front and back light panels for handheld video game devices; and high-frequency cordless telephones and home feature phones. The companya�s LCD Products segment manufactures LCD products for watches and medical instruments, white goods and industrial applications, automotive parts and appliances, car audio systems, hand held products, VoIP phones, and office automation applications. Nam Tai operates in Hong Kong, Europe, China, North America, Japan, and Korea. The company was founded in 1975 and is headquartered in Shenzhen, the Peoplea�s Republic of China.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641